Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product

Rhea-AI Summary

Polyrizon (Nasdaq: PLRZ) reported preclinical ex-vivo results on Dec 3, 2025 showing its proprietary naloxone Trap and Target (T&T) hydrogel adhered to rabbit nasal mucosa longer than a marketed intranasal naloxone spray.

In a 30-minute simulated nasal wash study using residual fluorescence quantification, the hydrogel retained significantly higher fluorescence than the commercial product (p < 0.0001, two-way ANOVA), indicating stronger mucoadhesion that may support prolonged nasal residence and potentially improved intranasal absorption.

Positive

• Ex-vivo study showed higher residual fluorescence versus commercial product
• Difference reached p < 0.0001 (two-way ANOVA)
• 30-minute simulated nasal wash protocol demonstrated durable retention
• Results support T&T hydrogel potential to improve nasal residence time

Negative

• Data are preclinical ex-vivo; no human PK or clinical efficacy reported
• No pharmacokinetic, onset-of-action, or clinical safety data provided
• No timeline or regulatory pathway for naloxone program disclosed

News Market Reaction – PLRZ

-3.27% 3.4x vol

59 alerts

-3.27% News Effect

+237.6% Peak Tracked

-9.6% Trough Tracked

-$511K Valuation Impact

$15M Market Cap

3.4x Rel. Volume

On the day this news was published, PLRZ declined 3.27%, reflecting a moderate negative market reaction. Argus tracked a peak move of +237.6% during that session. Argus tracked a trough of -9.6% from its starting point during tracking. Our momentum scanner triggered 59 alerts that day, indicating high trading interest and price volatility. This price movement removed approximately $511K from the company's valuation, bringing the market cap to $15M at that time. Trading volume was very high at 3.4x the daily average, suggesting heavy selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Study duration: 30-minute period P-value: p < 0.0001 Shelf registration size: $50,000,000 +5 more

8 metrics

Study duration 30-minute period Ex-vivo rabbit nasal mucosa wash experiment

P-value p < 0.0001 Two-way ANOVA comparing hydrogel to commercial naloxone spray

Shelf registration size $50,000,000 Form F-3 shelf filed on 2025-11-07

Reverse split ratio 1-for-6 Reverse share split effective for Nasdaq trading on Nov 28, 2025

Pre-split shares 6,250,053 shares Issued and outstanding ordinary shares before reverse split

Post-split shares 1,041,676 shares Issued and outstanding ordinary shares after reverse split

Ownership limit 4.99% Beneficial ownership cap for certain warrants

Ownership limit 9.99% Higher beneficial ownership cap for certain warrants

Market Reality Check

Price: $14.30 Vol: Volume 486,207 is far bel...

low vol

$14.30 Last Close

Volume Volume 486,207 is far below the 20-day average of 9,510,406 (relative volume 0.05). low

Technical Price $12.405 is trading below the 200-day MA at $218.52 and far under the $7,200 52-week high.

Peers on Argus

PLRZ was up 3.82% while key biotech peers like TTNP, ADTX, ENSC, SILO, and SXTP ...

1 Up

PLRZ was up 3.82% while key biotech peers like TTNP, ADTX, ENSC, SILO, and SXTP showed same-day declines, and only ENSC appeared on the momentum scanner with a 5.6% gain without news, pointing to stock-specific rather than sector-wide drivers.

Historical Context

5 past events · Latest: Dec 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 08	FDA interaction	Positive	-15.7%	FDA pre-submission meeting for PL-14 Allergy Blocker nasal spray development.
Dec 04	Manufacturing milestone	Positive	+104.0%	Larger-scale batches of PL-14 hydrogel produced meeting quality and stability specs.
Dec 03	Preclinical data	Positive	-3.3%	Preclinical mucoadhesion data showing T&T naloxone hydrogel outperforms marketed spray.
Dec 02	Scale-up validation	Positive	+132.0%	Successful scale-up run for PL-14 validating larger-batch production parameters.
Nov 06	Viral blocker data	Positive	-5.3%	In‑vitro data for PL‑16 showing reversible broad-spectrum viral blocking with no cytotoxicity.

Pattern Detected

Recent positive news has produced mixed reactions, with 3 negative and 2 positive price moves despite largely constructive operational and clinical updates.

Recent Company History

This announcement adds to a sequence of operational and R&D milestones in late 2025. On Dec 2, Polyrizon reported a key manufacturing upscaling milestone for PL-14, followed by large positive price moves. Further manufacturing scale-up and strategic positioning of the PL-14 Allergy Blocker platform were highlighted on Dec 2–4. The company also reported broad-spectrum viral blocking for PL‑16 on Nov 6. Despite generally positive scientific and regulatory updates, several prior news events saw negative next-day price reactions, underscoring inconsistent trading responses.

Regulatory & Risk Context

Active S-3 Shelf · $50,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-07

$50,000,000 registered capacity

An effective Form F-3 shelf registration would allow Polyrizon to offer up to $50,000,000 of securities, including ordinary shares, warrants, and units in future takedowns, providing capital-raising flexibility that could be dilutive depending on structure and timing.

Market Pulse Summary

This announcement adds statistically strong preclinical support (p 0.0001) for Polyrizon’s intranasa...

Analysis

This announcement adds statistically strong preclinical support (p < 0.0001) for Polyrizon’s intranasal naloxone hydrogel, complementing earlier stability findings and recent manufacturing scale-up milestones. It reinforces the broader T&T platform thesis within intranasal drug delivery. At the same time, the company has a $50,000,000 Form F‑3 shelf and recently executed a 1‑for‑6 reverse split, both relevant for capital structure. Investors may watch for clinical initiation, regulatory interactions, and any takedowns from the shelf.

Key Terms

mucoadhesion, naloxone, intranasal, Simulated Nasal Electrolyte Solution (SNES), +4 more

8 terms

mucoadhesion medical

"Superior Mucoadhesion may potentially Translate into More Reliable Opioid Overdose"

Mucoadhesion is the ability of a drug, medical device or formulation to stick to mucous membranes lining the nose, mouth, throat, eyes or gut, using materials that adhere to wet tissue. For investors it matters because mucoadhesive products can deliver medicine more reliably, extend how long a drug acts, reduce dosing frequency and improve patient convenience—features that can increase a product’s effectiveness, market appeal and commercial value.

naloxone medical

"its proprietary naloxone hydrogel adheres to nasal tissue longer than an approved"

Naloxone is a fast-acting medication that temporarily reverses the life-threatening effects of opioid overdose by blocking opioids’ effects on the brain, like an emergency master key that unlocks someone from a dangerous drug-induced shutdown. It matters to investors because demand, pricing, regulatory approvals, product formulations (injectable, nasal spray), and government purchasing programs can drive sales, affect company valuations, and influence litigation and public-health-related revenue streams.

intranasal medical

"development of intranasal products, today announced compelling new preclinical data"

Administration or delivery of a drug or vaccine through the nose, typically via a spray or drops that are absorbed by the nasal tissues. For investors, intranasal products can matter because they often offer easier, needle-free use, faster onset of effect, and potential cost or compliance advantages that can widen a product’s market and affect regulatory review, manufacturing complexity, and commercial prospects — similar to how a convenient app can outsell a clunky desktop program.

Simulated Nasal Electrolyte Solution (SNES) medical

"washing with Simulated Nasal Electrolyte Solution (SNES) over a 30-minute period."

A simulated nasal electrolyte solution (SNES) is a laboratory-made fluid formulated to mimic the salt, pH and moisture of human nasal secretions. Researchers and manufacturers use it like a stand‑in for real mucus when testing nasal sprays, drug delivery devices, filters or packaging so results are predictable and repeatable. For investors, SNES matters because successful testing with this standard fluid helps products meet regulatory requirements and reach market faster, reducing development risk.

two-way ANOVA technical

"p < 0.0001, two-way ANOVA), indicating notably stronger and more durable"

Two-way ANOVA is a statistical test that compares average outcomes across groups defined by two separate categorical factors and also checks whether those two factors interact to change the outcome. For investors, it helps determine whether differences in measures like sales, returns or survey responses are linked to two distinct influences (for example region and marketing type) and whether the combination of those influences produces a different effect than each one alone, guiding resource allocation and hypothesis testing.

bioavailability medical

"supporting potentially prolonged contact at the nasal deposition site and potentially enhancing bioavailability."

Bioavailability is the measure of how much and how quickly a substance, such as a medication or nutrient, enters the bloodstream and becomes available for use by the body. For investors, it matters because it influences how effectively a product works and how quickly results are seen, which can impact a company's success and the potential value of related investments. Think of it like how much of a medicine actually reaches your bloodstream after taking it—that determines how well it can do its job.

preclinical medical

"today announced compelling new preclinical data showing its proprietary naloxone"

Preclinical describes the stage of drug or medical-product development when researchers test a candidate in the lab and in animals to see if it is safe, reaches intended targets, and shows basic effectiveness before any human trials begin. For investors, preclinical status signals an early, higher‑risk opportunity where positive lab results can increase value but significant work, time, and regulatory hurdles remain — like proofing a prototype in a workshop before road testing.

hydrogel medical

"its proprietary naloxone hydrogel adheres to nasal tissue longer than an"

A hydrogel is a soft, jelly-like material made mostly of water combined with a network of flexible, supportive molecules. Its unique ability to hold large amounts of water while remaining stable makes it useful in various medical, industrial, and consumer applications. For investors, innovations involving hydrogels can signal growth opportunities in sectors like healthcare, biotechnology, and advanced materials.

AI-generated analysis. Not financial advice.

Superior Mucoadhesion may potentially Translate into More Reliable Opioid Overdose Reversal in Real-World Emergencies

Ra’anana, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing on the development of intranasal products, today announced compelling new preclinical data showing its proprietary naloxone hydrogel adheres to nasal tissue longer than an approved and marketed intranasal naloxone spray product.

Using an established ex-vivo rabbit nasal mucosa model, researchers evaluated the persistence of Polyrizon’s hydrogel formulation versus commercial product by applying each formulation to mucosal tissue and washing with Simulated Nasal Electrolyte Solution (SNES) over a 30-minute period. Quantification of residual fluorescence revealed that Polyrizon’s hydrogel maintained higher values of the fluorescence marker when compared to the commercial product, with differences reaching high statistical significance (p < 0.0001, two-way ANOVA), indicating notably stronger and more durable mucosal retention.

The results showed that Polyrizon’s Trap and Target ™ (T&T) hydrogel exhibited significantly higher mucoadhesion levels compared to the commercial product, supporting potentially prolonged contact at the nasal deposition site and potentially enhancing bioavailability.

Improved mucoadhesion is a critical factor for intranasal drug delivery - particularly for emergency treatments such as opioid overdose reversal - because enhanced residence time at the nasal deposition site can support more reliable absorption and potentially faster onset of action.

“We believe that these outcomes further validate the potential of our T&T hydrogel platform and highlight its unique advantages in intranasal drug delivery,” said Tomer Izraeli, CEO of Polyrizon. “The ability to significantly outperform an existing marketed product in mucoadhesion is an important milestone as we continue advancing our Naloxone program.”

This new dataset builds directly on the previously reported encouraging stability results, which demonstrated the robustness of Polyrizon’s formulation under various storage conditions. Collectively, stability plus mucoadhesion performance reinforce the potential of Polyrizon’s T&T technology to deliver a safer, more reliable, and more effective intranasal Naloxone product.

About Polyrizon

Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses how superior mucoadhesion for its intranasal naloxone hydrogel may potentially translate into more reliable opioid overdose reversal in real-world emergencies, its belief that that the result further validate the potential of its T&T hydrogel platform and highlight its unique advantages in intranasal drug delivery, advancing its Naloxone program and the potential of Polyrizon’s T&T technology to deliver a safer, more reliable, and more effective intranasal Naloxone product . Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on March 11, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.

Contacts:

Michal Efraty

Investor Relations

IR@polyrizon-biotech.com

FAQ

What did Polyrizon (PLRZ) announce on December 3, 2025 about its naloxone hydrogel?

Polyrizon announced preclinical ex-vivo results showing its T&T naloxone hydrogel had significantly greater mucoadhesion than a marketed intranasal naloxone spray (p < 0.0001).

How was mucoadhesion measured in Polyrizon's Dec 3, 2025 study for PLRZ?

Researchers used an ex-vivo rabbit nasal mucosa model with a 30-minute simulated nasal electrolyte wash and quantified residual fluorescence to compare formulations.

Does Polyrizon's mucoadhesion result for PLRZ prove better clinical opioid overdose reversal?

No; the result shows stronger ex-vivo mucoadhesion, but no human pharmacokinetic or clinical efficacy data were reported to confirm clinical performance.

What is the statistical significance reported by Polyrizon for the PLRZ hydrogel results?

The company reported differences reaching p < 0.0001 using a two-way ANOVA.

What potential benefits did Polyrizon cite for PLRZ's improved mucoadhesion?

Polyrizon said improved mucoadhesion may support prolonged nasal residence and potentially enhance bioavailability and reliability of intranasal naloxone delivery.